The National Institute of Allergy and Infectious Diseases (NIAID), has awarded 12 institutes with grants towards phage therapy research.
superbugs
Phico Therapeutics receives funding from CARB-X towards the development of engineered bacteriophage with SASP gene targeting Pseudomonas aeruginosa.
Synthetic bacteriophages with shortened genome created successfully by scientists from CEB – Centre of Biological Engineering, Braga in Portugal.
Research shows an opportunity in using a combination of bacteriophages with antibiotics against superbugs.